The corresponding relative risk reduction is quite depending on the tumor biology than about the nodal status and extent of condition [62]. The recommendation is in part according to new evidence resulting from a systematic evaluation in the Cochrane Collaboration [102]. Reviewing the information of RCTs coping with hypofractionated https://johns642nve9.wikievia.com/user